Rigel Pharmaceuticals (RIGL) Key Ratios

$48.50

up-down-arrow $-0.92 (-1.86%)

As on 03-Sep-2026 16:01EDT

Market cap

info icon

$868 Mln

Revenue (TTM)

info icon

$277 Mln

P/E Ratio

info icon

2.8

P/B Ratio

info icon

2.1

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 33.81 -22.60 3.31 29.77 13.94
EBIT 86.13 -60.61 -14.50 68.55 91.67
Net Profit 99.79 -71.00 229.08 118.08 112.80
EPS 100.98 -73.08 214.18 114.00 101.44
Book Value -- -- 11,266.61 -- 59.50
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info 14.32-2.2033.0243.8914.66
Net Margin info ---30.22116.30----
Return on equity info 55.59-117.5878.81185.94-137.92
Return on Capital info 32.47-12.23--144.4936.74
Return on Assets info 33.619.8270.75108.3412.44
Debt to Equity (x) info ----0.000.1418.24
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
--
144.49
36.74
-83.82
-131.81
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

78.81

Higher than Peers by 119.21

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
78.81
185.94
-137.92
118.75
-699.05
Peer Median
-40.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

70.75

Higher than Peers by 101.73

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
70.75
108.34
12.44
-19.95
-38.84
Peer Median
-30.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

33.02

Higher than Peers by 116.63

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
33.02
43.89
14.66
-15.59
-45.63
Peer Median
-83.62
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

116.30

Higher than Peers by 208.97

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
116.30
124.72
9.75
-21.47
-48.44
Peer Median
-92.67
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

Higher than Peers by 0.00

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
0.00
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

3.31

Lower than Peers by 50.64

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
3.31
0.64
0.53
-0.03
-0.19
Peer Median
53.95
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-14.50

Lower than Peers by 13.70

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
-14.50
391.35
244.27
66.79
-340.73
Peer Median
-0.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

229.08

Higher than Peers by 236.38

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
229.08
1,999.08
169.69
57.16
-226.97
Peer Median
-7.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

214.18

Higher than Peers by 199.53

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
214.18
19.04
1.68
0.58
-2.24
Peer Median
14.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

381.87

Higher than Peers by 392.05

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
381.87
--
--
--
--
Peer Median
-10.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
--
0.14
18.24
-2.11
-3.05
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.09

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
0.09
0.08
2.30
-0.28
-0.08
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.95

Lower than Peers by 3.86

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
1.95
2.42
2.13
1.86
1.78
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.79

Lower than Peers by 3.90

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
1.79
2.30
2.04
1.76
1.64
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

15.74

Higher than Peers by 17.83

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
15.74
17.64
3.32
-2.65
-14.80
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

20.25

Higher than Peers by 1.11

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
20.25
17.59
23.21
26.14
33.53
Peer Median
19.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.61

Higher than Peers by 0.54

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
0.61
0.87
1.28
0.93
0.80
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
--
57.95
73.51
110.73
84.74
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
--
162.96
112.86
376.04
1,642.89
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
--
98.01
102.65
761.58
2,746.48
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
--
122.90
83.73
-274.81
-1,018.84
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

2.77

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
2.77
2.20
17.30
-1.01
-0.44
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

2.06

Lower than Peers by 3.13

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
2.06
2.06
92.01
-0.88
-1.90
Peer Median
5.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

8.71

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
8.71
5.36
10.00
-1.70
-0.17
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

868

Higher than Peers by 722

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Rigel Pharmaceuticals (RIGL)
868
--
--
--
--
Peer Median
146
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...